Magnus Financial Group LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 4 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Magnus Financial Group LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$73,000
-24.7%
19,1400.0%0.01%
-28.6%
Q4 2019$97,0000.0%19,1400.0%0.01%
-22.2%
Q3 2019$97,000
-17.8%
19,1400.0%0.02%
-21.7%
Q2 2019$118,000
+32.6%
19,1400.0%0.02%
+27.8%
Q1 2019$89,000
+17.1%
19,140
+5.4%
0.02%
-10.0%
Q4 2018$76,00018,1630.02%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders